Date: 2015-09-23
Type of information: R&D agreement
Compound: Tau diagnostic assay
Company: AC Immune (Switzerland) Nestlé Institute of Health Sciences (Switzerland)
Therapeutic area: Diagnostic - Neurodegenerative diseases
Type agreement: R&D collaboration
Action mechanism:
Disease: Alzheimer’s disease
Details: * On September 23, 2015, AC Immune and the Nestlé Institute of Health Sciences SA (NIHS), a fundamental research institute of the global nutrition, health and wellness company Nestlé, announced that they have signed a research collaboration agreement to develop a novel, minimally invasive Tau diagnostic assay for the early diagnosis of Alzheimer’s disease. Under the terms of the agreement AC Immune will provide its world leading expertise in the biology and pathology of Tau as well as committing its laboratory capabilities to support the collaborative research program. NIHS will apply its proprietary multiplexed antibody technology platform to the research program with the goal of identifying and validating a highly sensitive diagnostic assay for the detection of Tau in human cerebrospinal fluid (CSF) and blood plasma. Nestlé’s proprietary multiplexed ultrasensitive triplex antibody technologyis a patented diagnostic antibody-based platform capable of measuring soluble proteins with high sensitivity and specificity. The technology was developed by Prometheus Laboratories Inc., a Nestlé Health Science company. Since 2013, NIHS has applied it in Brain Health research, specifically in Alzheimer’s. The assay uses a triplex antibody microarray-based platform that measures the expression and activation of target proteins in tissues, blood or other fluids.
Financial terms: Financial terms were not disclosed.
Latest news:
